#chlamydia

This video is about disclosing HIV status on dating apps.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

It is unclear how going on Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) may have affected these rates.

However, might post-exposure prophylaxis (PEP) against STIs impact resistance to antibiotics among infections like gonorrhea?

A modeling study suggests that HIV meds’ effects on the immune response may partially explain the recent rise in syphilis in gay and bi men.

Men who have sex with men (MSM) account for most new cases of gonorrhea and syphilis.

The CDC’s first state-by state breakdown of rates of the STI among men who have sex with men reveals a heavy burden in the South.

The World Health Organization has recommended updated treatment protocols to combat drug-resistant gonorrhea, chlamydia and syphilis.

PrEP use and high STI rates are connected, but more research is needed to determine whether starting PrEP actually causes STI rates to rise.

The U.S. sexually transmitted infection epidemic is expanding, in some cases at an “alarming rate,” according to the CDC.

Among people with HIV, chlamydia and gonorrhea infections in the rectum do not influence the likelihood of transmitting the virus to others.

Taking a daily dose of the antibiotic doxycycline may be an effective form of pre-exposure prophylaxis against various bacterial sexually...

A daily dose of the antibiotic doxycycline may be effective as pre-exposure prophylaxis (PrEP) against gonorrhea, chlamydia and syphilis.

U.S. syphilis rate is continuing its steady climb, with men who have sex with men (MSM) driving a 10 percent increase between 2012 and 2013.